Recent ME News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 12:06:02 PM
- 23andMe Therapeutics Announces Positive Preliminary Phase 2 Safety and Efficacy Results for 23ME-00610, targeting CD200R1, at the 2024 ASCO Annual Meeting • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Largest study on the LRRK2 variant leads to discoveries about health, ancestry, and history • GlobeNewswire Inc. • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 08:06:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/23/2024 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/23/2024 08:07:02 PM
- 23andMe Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results • GlobeNewswire Inc. • 05/23/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:07:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/21/2024 08:06:05 PM
- Lemonaid Health Now Offers Prescription ED Medication STENDRAⓇ Through Collaboration with Petros Pharmaceuticals • GlobeNewswire Inc. • 05/14/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:06:05 PM
- 23andMe to Report Q4 and Full Year FY2024 Financial Results • GlobeNewswire Inc. • 05/09/2024 08:50:07 PM
- Potter Handy Law Firm Represents Nearly 5,000 Clients in 23andMe Data Breach Case • Business Wire • 04/30/2024 03:00:00 PM
- 23andMe to Present Preliminary Efficacy and Biomarker Data for 23ME-00610 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 04/24/2024 08:05:00 PM
- 23andMe announces CEO’s intention to pursue a potential take-private • GlobeNewswire Inc. • 04/18/2024 12:00:00 PM
- 23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 04/05/2024 08:05:00 PM
- 23andMe Initiates Phase 1 Clinical Trial for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 • GlobeNewswire Inc. • 03/20/2024 11:30:00 AM
- 23andMe Launches New Feature Connecting Customers to Historical Individuals from Hundreds and Even Thousands of Years Ago • GlobeNewswire Inc. • 03/19/2024 12:00:00 PM
- 23andMe Launches New Genetic Reports on Common Forms of Cancer • GlobeNewswire Inc. • 03/06/2024 12:30:00 PM
- 23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 • GlobeNewswire Inc. • 03/05/2024 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 09:36:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/07/2024 09:07:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 09:03:56 PM
- 23andMe Reports Third Quarter Fiscal 2024 Financial Results • GlobeNewswire Inc. • 02/07/2024 09:01:00 PM
- Moneta Gold and Nighthawk Gold Complete At-Market Merger to form STLLR Gold Inc. • Business Wire • 02/06/2024 12:00:00 PM
PickleJar Debuts Nationwide Contest With Brian Kelley for Fans to Win a Three-Day Bahama Cruise • NREG • Jun 3, 2024 8:45 AM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM